Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pay Per View: Why Fees for DTC Might Fly

This article was originally published in RPM Report

Executive Summary

The pharma industry is promising to preclear its ads with FDA. The problem is, FDA's ad review group is already overworked. Some in industry think the answer is to expand the user fee program to include fees for DTC.

You may also be interested in...



Pay TV: Get Ready for Direct to Consumer Advertising User Fees

FDA is proposing that drug sponsors assume responsibility for testing proprietary trademarks for potential medication errors before they are reviewed by the agency. That -- along with performance goals tied to user fee dollars -- should help speed up the review of proposed brand names.

The Benefits of Being Good

Since the implementation of the PhRMA direct-to-consumer advertising guidelines in January 2006, FDA hasn't taken a single enforcement action against a consumer-directed prescription drug print or TV ad. That's good news for an industry trying to quiet critics on Capitol Hill in the run-up of the reauthorization of the Prescription Drug User Fee Act.

Time to Pay the Piper? Industry Prepares for a Fight Over User Fees

The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel